Patient-derived liver organoids recapitulate liver epithelial heterogeneity and enable precision modeling of alcohol-related liver disease
Por:
Ariño, S, Ferrer-Lorente, R, Serrano, G, Zanatto, L, de la Torre, RAMG, Gratacos-Ginès, J, Rubio, AB, Pérez, M, Mateos-Sánchez, C, Aguilar-Bravo, B, Atkinson, S, Xu, ZQ, Cantallops-Vilà, P, Sererols-Viñas, L, Ruiz-Blázquez, P, Rill, A, Fundora, Y, Lozano, JJ, Coll, M, Ochoa, I, Affo, S, Moles, A, Mereu, E, Bataller, R, Pose, E and Sancho-Bru, P
Publicada:
1 ene 2026
Ahead of Print:
1 dic 2025
Resumen:
Background & aims: Animal models poorly recapitulate advanced alcohol-associated liver disease (ALD), precluding the development of new treatments. Organoids have emerged as a powerful human-based preclinical tool; however, current patient-derived liver organoids fail to capture epithelial heterogeneity and require surgical resections, limiting their use in personalized disease modeling. Here, we describe the development of organoids from liver needle biopsies (b-Orgs) obtained from patients with ALD. Methods: b-Orgs were generated from tru-cut biopsies from patients at early (n = 28) and advanced (n = 34) stages of ALD. b-Orgs were characterized by immunofluorescence, bulk and single-cell RNA sequencing, and compared to parental tissues. b-Orgs were used to model ALD progression, identify pathogenic drivers, induce alcohol-associated hepatitis and evaluate response to prednisolone. Results: Phenotypic and functional analysis of b-Orgs showed hepatocyte-enriched features. Single-cell RNA sequencing revealed a heterogeneous cell composition comprising hepatocyte, biliary and progenitor populations, mirroring the epithelial landscape found in patients with advanced ALD. Importantly, b-Orgs preserved disease stage features and revealed an association between ELF3, cell plasticity, and disease progression. Finally, stimulation of b-Orgs with drivers of ALD induced pathophysiological features of alcohol-associated hepatitis, including reactive oxygen species production, lipid accumulation, inflammation and decreased cell proliferation, which were attenuated by prednisolone. Conclusions: We describe a human-based model that captures epithelial complexity and patient-specific features of ALD. This approach enables the identification of drivers of cell plasticity and highlights the potential of organoid-based liver disease modeling for personalized medicine. (c) 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver. This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
Filiaciones:
Ariño, S:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Hepat Digest C, Barcelona, Spain
Ferrer-Lorente, R:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Serrano, G:
CIMA Univ Navarra, Computat Biol Program, IdiSNA, Pamplona, Spain
Zanatto, L:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
de la Torre, RAMG:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Gratacos-Ginès, J:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Liver Unit, Barcelona, Spain
Rubio, AB:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Liver Unit, Barcelona, Spain
Pérez, M:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Liver Unit, Barcelona, Spain
Mateos-Sánchez, C:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Aguilar-Bravo, B:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Atkinson, S:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Imperial Coll London, Dept Metab Digest & Reprod, London, England
Xu, ZQ:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Cantallops-Vilà, P:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Sererols-Viñas, L:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Ruiz-Blázquez, P:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Hepat Digest C, Barcelona, Spain
CSIC, Inst Biomed Res Barcelona, Dept Expt Pathol, Barcelona, Spain
:
Josep Carreras Leukaemia Res Inst, Barcelona, Spain
Fundora, Y:
Hosp Clin Barcelona, Dept Gen & Digest Surg, Barcelona, Spain
Lozano, JJ:
Ctr Invest Biomed Red Enfermedades Hepat Digest C, Barcelona, Spain
Coll, M:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Univ Barcelona UB, Barcelona, Spain
Ochoa, I:
Univ Navarra, Dept Elect Engn TECNUN, San Sebastian, Spain
Univ Navarra, Data Sci & Artificial Intelligence Inst DATAI, Pamplona, Spain
Affo, S:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Moles, A:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Hepat Digest C, Barcelona, Spain
:
Josep Carreras Leukaemia Res Inst, Barcelona, Spain
Bataller, R:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Hepat Digest C, Barcelona, Spain
Hosp Clin Barcelona, Liver Unit, Barcelona, Spain
Univ Barcelona UB, Barcelona, Spain
Pose, E:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Hepat Digest C, Barcelona, Spain
Hosp Clin Barcelona, Liver Unit, Barcelona, Spain
Univ Barcelona UB, Barcelona, Spain
Sancho-Bru, P:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Hepat Digest C, Barcelona, Spain
Univ Barcelona UB, Barcelona, Spain
Bronze
|